Articles tagged "Heart transplant patients"

2020 American Transplant Congress
Taking it to the Max: Extremely Low LDL May Provide Benefit for Prevention of Cardiac Allograft Vasculopathy
R. Lee¹, E. J. Henricksen¹, Y. Moayedi², K. Y. Feng³, J. Han³, W. Yang⁴, R. Imai¹, J. J. Teuteberg⁴, K. K. Khush⁴
¹Pharmacy, Stanford Health Care, Stanford, CA, ²University Health Network, Toronto, ON, Canada, ³Medicine, Stanford University, Stanford, CA, ⁴Cardiac Transplant, Stanford University, Stanford, CA
*Purpose: Routine use of statins is the only Class I ISHLT recommendation in heart transplantation (HT) to reduce cardiac allograft vasculopathy (CAV) and improve survival.…
2020 American Transplant Congress
Circulating Tissue Specific Exosomes Enable Noninvasive Diagnosis of Acute Cellular Rejection in Clinical Heart Transplantation
L. Korutla¹, R. Hu¹, C. Romano¹, M. Molina¹, C. Sciortino², C. Mullan³, R. McGargle², H. Kagawa², A. Kilic², A. Naji⁴, P. Vallabhajosyula³
¹Surgery, University of Pennsylvania, Philadelphia, PA, ²Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Surgery, Yale University, New Haven, CT, ⁴University of Pennsylvania, Philadelphia, PA
*Purpose: There is a critical need for development of noninvasive biomarkers for allograft surveillance and diagnosis of rejection in heart transplant patients, as endomyocardial biopsy…
2020 American Transplant Congress
Prevalence, Prognosis and Predictors of Neurological Complications after Heart Transplantation
C. Caraviello, D. Harsanyi, L. Trevizan, F. Bacal, S. Mangini
Cardiology, Hospital Israelita Albert Einstein, São Paulo, Brazil
*Purpose: Heart transplantation (HT) is considered the gold-standard treatment for end-stage heart failure. In spite of its innumerous benefits, this therapy still involves complications. Among…
2020 American Transplant Congress
Barriers to Organ Transplantation among Underrepresented Racial and Ethnic Groups
M. Parra
Duke Clinical Research Institute, Durham, NC
*Purpose: To understand how known patient, provider, and system-level barriers to organ transplantation differ by race and ethnicity.*Methods: We searched Pubmed and Scopus for articles…
2020 American Transplant Congress
Dosing and Outcomes of Conversion to Extended-Release Tacrolimus in Heart and Lung Transplant Recipients
C. Doligalski¹, K. Walter¹, P. Chang², L. J. Lobo²
¹University of North Carolina Medical Center, Chapel Hill, NC, ²Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
*Purpose: Extended release tacrolimus (LCP-Tac) is a novel once daily formulation with improved pharmacokinetic parameters compared to immediate release tacrolimus (IR-Tac). LCP-Tac use in renal…
2020 American Transplant Congress
The Importance of Annual Medicare Part D Plan Evaluation in Heart Transplantation
L. M. Lourenco
Pharmacy Services, University of Chicago Medicine, Chicago, IL
*Purpose: The Medicare open enrollment period is from Oct 15 to Dec 7, annually. The purpose of this project was to objectively measure the benefit…
2020 American Transplant Congress
Investigating the 6-Month Effects of the UNOS Allocation System Changes on the Post Transplant Outcomes in Patients with Amyloidosis
P. Banankhah¹, G. Liu¹, J. Nattiv¹, C. Lum², A. Salimbangon³, A. Wolfson⁴, E. DePasquale¹, R. Chand⁵, P. Genyk¹, P. Kingsford¹, J. Li¹, D. Vucicevic⁶, A. Vaidya¹, K. Pandya¹, J. Rahman¹, M. Fong¹, L. Grazette¹, A. Kiankhooy¹, S. Hashmi¹, S. Nuno¹, J. Pizula¹, D. Miklin¹, A. E. Lee¹, K. Yang¹, S. Shah¹
¹Cardiology, University of Southern California, Los Angeles, CA, ²Cardiology, The Queen's Medical Center, Honolulu, HI, ³Cardiology, UCLA Medical Center, Los Angeles, CA, ⁴Cardiology, University of Arizona Sarver Heart Center, Tucson, AZ, ⁵Cardiology, Harbor-UCLA Medical Center, Los Angeles, CA, ⁶Cardiology, Newark Beth-Israel Medical Center, Newark, NJ
*Purpose: Cardiac amyloidosis is an infiltrative cardiomyopathy with poor outcomes. Cardiac transplantation and increased utilization of mechanical support have led to improved outcomes in patients…
2020 American Transplant Congress
Multiplicity of Non-HLA Targets for Antibodies Developed in Association with Ventricular Assist Device Implantation
M. Askar, D. Bhakta, H. Zafar, A. Alam, L. Pittmon, S. Kang, L. Klingman, J. Felius, S. M. Joseph, D. Wencker, D. M. Meyer, S. A. Hall
Baylor University Medical Center and Baylor Scott & White Research Institute, Dallas, TX
*Purpose: Multiple non-HLA antibodies have been implicated in poor outcomes after heart transplantation. Development of HLA and Non-HLA antibodies have been reported in association with…
2020 American Transplant Congress
Impact of Alemtuzumab Induction on Cardiac Allograft Vasculopathy in Orthotopic Heart Transplant Recipients
M. Plazak¹, X. Gao², S. Gale², B. Reed², R. Madathil¹, S. Hammad¹, B. Ravichandran¹
¹University of Maryland Medical Center, Baltimore, MD, ²University of Maryland School of Pharmacy, Baltimore, MD
*Purpose: Cardiac allograft vasculopathy (CAV) is impacted by acute rejection and ultimately limits long-term survival of orthotopic heart transplant (OHT) recipients, thus there is interest…
2020 American Transplant Congress
Association between Homograft Tissue Exposure and Pre-Sensitization Prior to Heart Transplant in Patients with Congenital Heart Disease
D. J. Donovan¹, M. E. Richmond², E. A. Bacha³, L. J. Addonizio², W. A. Zuckerman²
¹Pediatrics, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, New York, NY, ²Pediatric Cardiology, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, New York, NY, ³Pediatric Cardiac Surgery, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, New York, NY
*Purpose: Surgical repair for patients with congenital heart disease (CHD) often incorporates homograft tissue or other biologic material, which can lead to pre-sensitization. We sought…

« Previous Page
1
…
8
9
10
11
12
…
30
Next Page »